FDA Keen On Lilly’s Prasugrel: Will Advisory Committee Follow Suit?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says that increased risk of bleeding for prasugrel’s clear cardiovascular efficacy is a “reasonable trade.”